Mylan Inc.
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1961-01-01
- Employees
- 35K
- Market Cap
- -
- Website
- https://www.mylan.com/
Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 924
- Registration Number
- NCT05158972
- Locations
- 🇭🇰
Asia Priority Healthcare, Kowloon, Hong Kong
🇲🇾Kempas Medical Center, Johor Bahru, Malaysia
🇲🇾University Malaya Medical Centre, Kuala Lumpur, Malaysia
Study to Evaluate the Effectiveness of Legalon®
- First Posted Date
- 2021-09-21
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 362
- Registration Number
- NCT05051527
- Locations
- 🇹🇭
Phramongkutklao Hospital, 315 Ratchawithi Rd, Thung Phaya Thai, Ratchathewi, Bangkok, Thailand
Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)
- First Posted Date
- 2021-09-01
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT05030025
- Locations
- 🇨🇦
Altasciences, Montréal, Quebec, Canada
Observation of the Effects of Guideline-driven Lifestyle Interventions, Including Use of a Red-yeast Based Nutraceutical
- Conditions
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 259
- Registration Number
- NCT05000541
- Locations
- 🇩🇪
AmBeNet GmbH, Leipzig, Germany
🇩🇪Medical Practice, Görlitz, Germany
🇦🇹Ordination, Vienna, Austria
Observational Study to Evaluate the Actual Use of Elidel® in Chinese Patients With Mild to Moderate Atopic Dermatitis
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT04976868
- Locations
- 🇨🇳
The first Hospital of China Medical University, Shenyang, China
🇨🇳Peking University Shenzhen Hospital, Shenzhen, China
🇨🇳Children's Hospital Capital Institute of Pediatrics, Beijing, China
Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental Pain
- Conditions
- Interventions
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2022-08-08
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 114
- Registration Number
- NCT04571515
- Locations
- 🇺🇸
Research Facility 101, Salt Lake City, Utah, United States
Mylan Insulin Aspart Study
- Conditions
- Interventions
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 478
- Registration Number
- NCT03760068
- Locations
- 🇺🇸
Atlanta Diabetes Associates, Atlanta, Georgia, United States
🇺🇸Hanson Clinical Research Center, Port Charlotte, Florida, United States
🇺🇸Diabetes Research Center, Tustin, California, United States
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
- Conditions
- Interventions
- First Posted Date
- 2018-06-29
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT03573817
- Locations
- 🇺🇸
Theravance Biopharma Investigational Site, Spartanburg, South Carolina, United States
Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT03502070
- Locations
- 🇺🇸
Batchelor Childrens Research Institute, Miami, Florida, United States
🇺🇸University of Miami Hospital, Miami, Florida, United States
🇺🇸Nemours Childrens Hospital, Orlando, Florida, United States
Mylan Insulin Glargine Study
- Conditions
- Interventions
- First Posted Date
- 2017-12-18
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 219
- Registration Number
- NCT03376789
- Locations
- 🇺🇸
Mylan Investigator Site, Dallas, Texas, United States